日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Incremental Burden of Pulmonary Hypertension Among Patients With Interstitial Lung Disease in the Real-World Setting

真实世界中间质性肺病患者肺动脉高压负担的增加

Burger, Charles D; Wu, Jasmanda; O'Brien, Gerald; Makulova, Natalya; Ward, Trevor; Shamsunder, Meghana G; Shah, Bonny; Safdar, Zeenat

Qualitative Interviews Exploring Adverse Event Mitigation Strategies in Adults Receiving Amikacin Liposome Inhalation Suspension

通过定性访谈探索接受阿米卡星脂质体吸入混悬液治疗的成年患者的不良事件缓解策略

Ali, Juzar; Wu, Jasmanda; Hassan, Mariam; Tsai, Jui-Hua; Touba, Nancy; McCarrier, Kelly; Ballard, Mark; Chatterjee, Anjan

Pulmonary exacerbations in insured patients with bronchiectasis over 2 years

两年内,患有支气管扩张症的参保患者肺部急性加重情况

Flume, Patrick A; Feliciano, Joseph; Lucci, Matthew; Wu, Jasmanda; Fucile, Sebastian; Hassan, Mariam; Chatterjee, Anjan

Impact of initiation of amikacin liposome inhalation suspension on hospitalizations and other healthcare resource utilization measures: a retrospective cohort study in real-world settings

阿米卡星脂质体吸入混悬液的启动对住院率和其他医疗资源利用指标的影响:一项真实世界回顾性队列研究

Aksamit, Timothy; Wu, Jasmanda; Hassan, Mariam; Achter, Emily; Chatterjee, Anjan

Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world study

美国高低血糖风险2型糖尿病患者改用甘精胰岛素300 U/mL与第一代基础胰岛素类似物治疗的临床结局:来自DELIVER高风险真实世界研究的结果

Sullivan, Sean D; Freemantle, Nick; Gupta, Rishab A; Wu, Jasmanda; Nicholls, Charlie J; Westerbacka, Jukka; Bailey, Timothy S

How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real-world setting?

在真实世界中,有多少 2 型糖尿病患者符合随机对照试验(胰岛素甘精 300 U/mL)的入选标准?

Mauricio, Dídac; Westerbacka, Jukka; Nicholls, Charlie; Wu, Jasmanda; Gupta, Rishab; Eliasson, Björn

Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study

一项欧洲真实世界研究表明,2 型糖尿病患者改用/开始使用甘精胰岛素 300 U/ml 可降低低血糖风险(与 100 U/ml 相比):

Escalada, Javier; Bonnet, Fabrice; Wu, Jasmanda; Bonnemaire, Mireille; Gupta, Shaloo; Cambron-Mellott, Janelle M; Nicholls, Charlie; Müller-Wieland, Dirk

Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real-world study

DELIVER Naïve D 真实世界研究:2 型糖尿病成人患者在开始使用甘精胰岛素 300 单位/毫升或德谷胰岛素后,血糖控制和低血糖发生率相当

Sullivan, Sean D; Nicholls, Charlie J; Gupta, Rishab A; Menon, Arjun A; Wu, Jasmanda; Westerbacka, Jukka; Bosnyak, Zsolt; Frias, Juan P; Bailey, Timothy S

Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3)

在真实世界中,老年 2 型糖尿病患者改用 300 单位/毫升的甘精胰岛素(DELIVER 3)

Bailey, Timothy S; Wu, Jasmanda; Zhou, Fang L; Gupta, Rishab A; Menon, Arjun A; Berhanu, Paulos; Westerbacka, Jukka; Van Vleet, John; Blonde, Lawrence

Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study

利培酮治疗患者高泌乳素血症和垂体肿瘤检测中的潜在偏倚:一项基于索赔数据的研究

Gianfrancesco, Frank D; Pandina, Gahan; Mahmoud, Ramy; Wu, Jasmanda; Wang, Ruey H